Diligence memo · auto-generated · as of July 2, 2026
KALM Therapeutics, Inc.
KALM Therapeutics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
KALM Therapeutics, Inc. operates in Biotechnology, based in HUNTSVILLE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
KALM Therapeutics, Inc. has raised $590K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $590K on 2024-07-25.
Most recent recorded round closed around 2024-07-25.
Valuation (modeled)modeled
Provath models KALM Therapeutics, Inc. at approximately $2.6M (range $315K–$8.6M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.81× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era. Within the normal band (81% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 23 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 12% of Biotechnology peers (4293 compared).
Modeled value ranks above 6% of those peers.
Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.